Stable, Early-stage Biomarker for Diagnosis of Bacillus anthracis Infection and Anthrax Vaccine Development
- In vitro data available
- In vivo data available (animal)
CDC and collaborative researchers have developed this technology and confirmed the value of a anthrose biomarker assay as a potentially valuable tool in informing early-stage response decisions following potentially anthrax exposure with in vivo primate data. This invention may be used for development of point-of-care anthrax exposure tests, as well as therapeutics and vaccines directed against B. anthracis.
- Biodefense, biosecurity
- Point-of-care B. anthracis-exposure diagnostic
- Anthrax vaccine development
- Development of B. anthracis therapeutics
- Valuable tools for screening at-risk individuals following possible anthrax exposure
- May be developed as a rapid, lateral-flow assay for emergency point-of-care diagnosis
- In vivo primate studies validate efficacy as serologic biomarker following aerosolized spore exposure
- Anthrose biomarker assay readout is critically unaffected by ciprofloxacin (anti-anthrax) treatment